GMDA Gamida Cell Ltd

USD 0.00 -0.03 -100
Icon

Gamida Cell Ltd (GMDA) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Very Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 0

-0.03 (-100.00)%

USD 4.34M

N/A

USD 0.00(+0.00%)

USD 3.00 (-100.00%)

Icon

GMDA

Gamida Cell Ltd (USD)
COMMON STOCK | NSD
USD 0.00
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Very Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 4.34M

USD 3.00 (-100.00%)

USD 0.00

Gamida Cell Ltd (GMDA) Stock Forecast

Show ratings and price targets of :
N/A
(+0.00%)

Based on the Gamida Cell Ltd stock forecast from 1 analysts, the average analyst target price for Gamida Cell Ltd is not available over the next 12 months. Gamida Cell Ltd’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Gamida Cell Ltd is Very Bearish, which is based on 0 positive signals and 7 negative signals. At the last closing, Gamida Cell Ltd’s stock price was USD 0. Gamida Cell Ltd’s stock price has changed by -100.00% over the past week, -100.00% over the past month and -100.00% over the last year.

No recent analyst target price found for Gamida Cell Ltd
No recent average analyst rating found for Gamida Cell Ltd

Company Overview Gamida Cell Ltd

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic mali...Read More

https://www.gamida-cell.com

5 Nahum Heftsadie Street, Jerusalem, Israel, 91340

143

December

USD

USA

Adjusted Closing Price for Gamida Cell Ltd (GMDA)

Loading...

Unadjusted Closing Price for Gamida Cell Ltd (GMDA)

Loading...

Share Trading Volume for Gamida Cell Ltd Shares

Loading...

Compare Performance of Gamida Cell Ltd Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for GMDA

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Gamida Cell Ltd (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc +4.99 (+1.25%) USD107.38B 29.93 21.06

ETFs Containing GMDA

Symbol Name GMDA's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Gamida Cell Ltd (GMDA) Stock

Based on ratings from 1 analysts Gamida Cell Ltd's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 1 buy, sell and hold ratings.

Unfortunately we do not have enough data on GMDA's stock to indicate if its a good dividend stock.

Based on targets from 1 analysts, the average taret price for GMDA is USD 0.00 over the next 12 months. The maximum analyst target price is USD while the minimum anlayst target price is USD .

Unfortunately we do not have enough data on GMDA's stock to indicate if its overvalued.

The last closing price of GMDA's stock was USD 0.00.

The most recent market capitalization for GMDA is USD 4.34M.

Based on targets from 1 analysts, the average taret price for GMDA is projected at USD 0.00 over the next 12 months. This means that GMDA's stock price may go up by +0.00% over the next 12 months.

We can't find any ETFs which contains Gamida Cell Ltd's stock.

As per our most recent records Gamida Cell Ltd has 143 Employees.

Gamida Cell Ltd's registered address is 5 Nahum Heftsadie Street, Jerusalem, Israel, 91340. You can get more information about it from Gamida Cell Ltd's website at https://www.gamida-cell.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...